(TNGX) Tango Therapeutics - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US87583X1090

Stock: PRMT5 Inhibitors, Brain-Penetrant Agent, Immune Evasion Reverser

Total Rating 53

Risk 65

Buy Signal 0.68

Biotechnology » Biotechnology
Age: 5.4y

Market Cap: 1,609m
Avg Trading Vol: 29.7M USD

ATR: 7.08%
Peers RS (IBD): 95.50

EPS (Earnings per Share)

EPS CAGR: 43.61%
EPS Trend: 39.8%

Last SUE: 4.00
Qual. Beats: 1

Revenue

Rev. CAGR: 81.83%
Rev. Trend: 16.2%

Last SUE: 2.32
Qual. Beats: 1

Risk 5d forecast
Volatility	78.6%
Relative Tail Risk	-8.34%

Reward TTM
Sharpe Ratio	1.79
Alpha	271.73

Character TTM
Beta	1.673
Beta Downside	1.449

Drawdowns 3y
Max DD	91.46%
CAGR/Max DD	0.31

Description: TNGX Tango Therapeutics December 26, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) is a Boston-based precision-oncology biotech that targets methylthioadenosine-cooperative PRMT5 pathways. Its lead assets include TNG462 (a PRMT5 inhibitor in a combined Phase 1/2 trial for pancreatic and non-small-cell lung cancer) and TNG456, a brain-penetrant PRMT5 inhibitor being evaluated for glioblastoma, as well as TNG260, a repressor-element-1 silencing transcription inhibitor aimed at reversing immune evasion in LKB1-deficient lung tumors.

As of the latest 10-Q, Tango reported approximately $115 million in cash and marketable securities, giving it runway through Q4 2025 at its current burn rate of roughly $30 million per quarter. The PRMT5 inhibitor class has attracted $2.5 billion of cumulative R&D spend in 2023, reflecting strong investor interest in epigenetic targets, while the broader biotech sector is benefiting from a 12 % YoY increase in venture funding for early-stage oncology programs.

For a deeper, data-driven view of Tango’s valuation metrics and comparable peers, you might explore the analysis tools on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: -100.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.70 > 0.02 and ΔFCF/TA -34.89 > 1.0
NWC/Revenue: 218.5% < 20% (prev 606.7%; Δ -388.2% < -1%)
CFO/TA -0.69 > 3% & CFO -145.8m > Net Income -100.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 8.88 > 1.5 & < 3
Outstanding Shares: last quarter (111.0m) vs 12m ago 2.27% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 23.64% > 50% (prev 12.31%; Δ 11.33% > 0%)
Interest Coverage Ratio: -17.80 > 6 (EBITDA TTM -104.0m / Interest Expense TTM -5.98m)

Altman Z'' -15.00

A: 0.69 (Total Current Assets 163.8m - Total Current Liabilities 18.4m) / Total Assets 210.1m
B: -2.69 (Retained Earnings -564.4m / Total Assets 210.1m)
C: -0.38 (EBIT TTM -106.4m / Avg Total Assets 281.3m)
D: -11.26 (Book Value of Equity -564.2m / Total Liabilities 50.1m)
Altman-Z'' Score: -18.58 = D

What is the price of TNGX shares?

As of February 10, 2026, the stock is trading at USD 12.89 with a total of 2,880,312 shares traded.
Over the past week, the price has changed by +7.96%, over one month by +9.70%, over three months by +62.55% and over the past year by +372.16%.

Is TNGX a buy, sell or hold?

Tango Therapeutics has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy TNGX.

StrongBuy: 6
Buy: 2
Hold: 0
Sell: 0
StrongSell: 0

What are the forecasts/targets for the TNGX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	14.4	11.6%
Analysts Target Price	14.4	11.6%
ValueRay Target Price	14.6	13%

TNGX Fundamental Data Overview February 07, 2026

P/S = 24.201
P/B = 10.3765
Revenue TTM = 66.5m USD
EBIT TTM = -106.4m USD
EBITDA TTM = -104.0m USD
Long Term Debt = 34.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.10m USD (from shortTermDebt, last quarter)
Debt = 34.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -23.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.49b USD (1.61b + Debt 34.8m - CCE 152.8m)
Interest Coverage Ratio = -17.80 (Ebit TTM -106.4m / Interest Expense TTM -5.98m)
EV/FCF = -10.16x (Enterprise Value 1.49b / FCF TTM -146.8m)
FCF Yield = -9.84% (FCF TTM -146.8m / Enterprise Value 1.49b)
FCF Margin = -220.7% (FCF TTM -146.8m / Revenue TTM 66.5m)
Net Margin = -151.1% (Net Income TTM -100.5m / Revenue TTM 66.5m)
Gross Margin = unknown ((Revenue TTM 66.5m - Cost of Revenue TTM 1.80m) / Revenue TTM)
Tobins Q-Ratio = 7.10 (Enterprise Value 1.49b / Total Assets 210.1m)
Interest Expense / Debt = 1.67% (Interest Expense 581.0k / Debt 34.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -84.0m (EBIT -106.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.88 (Total Current Assets 163.8m / Total Current Liabilities 18.4m)
Debt / Equity = 0.22 (Debt 34.8m / totalStockholderEquity, last quarter 160.0m)
Debt / EBITDA = 0.23 (negative EBITDA) (Net Debt -23.6m / EBITDA -104.0m)
Debt / FCF = 0.16 (negative FCF - burning cash) (Net Debt -23.6m / FCF TTM -146.8m)
Total Stockholder Equity = 165.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.74% (Net Income -100.5m / Total Assets 210.1m)
RoE = -60.80% (Net Income TTM -100.5m / Total Stockholder Equity 165.3m)
RoCE = -53.17% (EBIT -106.4m / Capital Employed (Equity 165.3m + L.T.Debt 34.8m))
RoIC = -50.84% (negative operating profit) (NOPAT -84.0m / Invested Capital 165.3m)
WACC = 11.85% (E(1.61b)/V(1.64b) * Re(12.08%) + D(34.8m)/V(1.64b) * Rd(1.67%) * (1-Tc(0.21)))
Discount Rate = 12.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.62%
Fair Price DCF = unknown (Cash Flow -146.8m)
EPS Correlation: 39.85 | EPS CAGR: 43.61% | SUE: 4.0 | # QB: 1
Revenue Correlation: 16.25 | Revenue CAGR: 81.83% | SUE: 2.32 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.30 | Chg30d=+0.010 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=-1.29 | Chg30d=+0.000 | Revisions Net=+5 | Growth EPS=-44.0% | Growth Revenue=-88.1%

Additional Sources for TNGX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle